scholarly journals Varicella-Zoster Gastritis in a Liver Transplant Patient: A Call to Attention

2021 ◽  
Vol 05 (02) ◽  
pp. 1-1
Author(s):  
Víctor Escrich ◽  
◽  
Ángela Martinez ◽  
Berta Lapeña ◽  
Marta Mayorga ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Transplant Patient ◽  
Solid Organ Transplantation ◽  
Gastrointestinal Symptoms ◽  
Solid Organ ◽  
Liver Transplant Patient ◽  
Cutaneous Manifestations ◽  
Varicella Zoster ◽  
Acute Gastritis ◽  
Histologic Changes

The reactivation of the Varicella-zoster virus (VZV) is a rare cause of acute gastritis in adults. About 30 cases have been reported in the literature, mostly with immunocompromised patients and mainly after bone marrow transplantation or during the development of malignant hematological diseases. Clinically, it is usually accompanied by cutaneous manifestations. Here, we studied a case of VZV gastritis in a liver transplant (LT) patient. We described the main symptoms, endoscopic findings, histologic changes, and treatment of VZV gastritis. Till now, no case of acute gastritis due to the reactivation of VZV after solid organ transplantation had been reported [2–5]. This was the first reported case of acute gastritis by the reactivation of VZV after LT without cutaneous vesicular eruption. Gastrointestinal symptoms usually develop a week before the onset of fever and cutaneous manifestations. However, in some cases, like this one, vesicular rashes may be absent, making the diagnosis quite challenging. In conclusion, through this case, we suggest including VZV gastritis in the differential diagnosis of gastrointestinal symptoms after transplantation and informing about the response of VZV gastritis to treatment with oral acyclovir.

Histologic changes resembling acute rejection in a liver transplant patient treated with terbinafine

2003 ◽  
Vol 34 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Michael O. Lovell ◽  
Kermit V. Speeg ◽  
Russell D. Havranek ◽  
Francis E. Sharkey
Keyword(s):  
Acute Rejection ◽  
Liver Transplant ◽  
Transplant Patient ◽  
Liver Transplant Patient ◽  
Histologic Changes

scholarly journals Mending a Broken Heart: Treatment of Stress-Induced Heart Failure after Solid Organ Transplantation

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
N. Thao Galván ◽  
Kayla Kumm ◽  
Michael Kueht ◽  
Cindy P. Ha ◽  
Dor Yoeli ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiogenic Shock ◽  
Liver Transplant ◽  
Organ Transplantation ◽  
Transplant Patient ◽  
Solid Organ Transplantation ◽  
Kidney Transplant Patient ◽  
Solid Organ ◽  
Takotsubo Syndrome ◽  
Transplant Patients

Stress-induced heart failure, also known as Broken Heart Syndrome or Takotsubo Syndrome, is a phenomenon characterized as rare but well described in the literature, with increasing incidence. While more commonly associated with postmenopausal women with psychiatric disorders, this entity is found in the postoperative patient. The nonischemic cardiogenic shock manifests as biventricular failure with significant decreases in ejection fraction and cardiac function. In a review of over 3000 kidney and liver transplantations over the course of 17 years within two transplant centers, we describe a series of 7 patients with Takotsubo Syndrome after solid organ transplantation. Furthermore, we describe a novel approach of successfully treating the transient, though potentially fatal, cardiogenic shock with a percutaneous ventricular assistance device in two liver transplant patients, while treating one kidney transplant patient medically and the remaining four liver transplant patients with an intra-aortic balloon pump. We describe our experience with Takotsubo’s Syndrome and compare the three modalities of treatment and cardiac augmentation. Our series is novel in introducing the percutaneous ventricular assist device as a more minimally invasive intervention in treating nonischemic heart failure in the solid organ transplant patient, while serving as a comprehensive overview of treatment modalities for stress-induced heart failure.

Disseminated cerebral fusariosis in a liver-transplant patient: A case report and review of the literature

2021 ◽  
Author(s):  
Pernilla Stropnicky ◽  
Katharina Heß ◽  
Thomas Becker ◽  
Felix Braun
Keyword(s):  
Transplant Patient ◽  
Distress Syndrome ◽  
Case Reports ◽  
Solid Organ Transplantation ◽  
Invasive Infection ◽  
Solid Organ ◽  
Fusarium Spp ◽  
Liver Transplant Patient ◽  
Complicated Course ◽  
Brain Abscesses

AbstractFusarium spp. can cause invasive infection with fatal outcomes in immunocompromised patients. Therefore, invasive fusariosis is rare after solid organ transplantation. For this reason, experience and management are limited to single published case reports.We report a 65-year-old female patient with disseminated brain abscesses caused by Fusarium after liver transplantation (LT). The patient underwent LT for secondary sclerosing cholangitis after acute respiratory distress syndrome (ARDS). After a complicated course with aneurysm and thrombosis of the hepatic artery, re-transplantation was performed after one month. Due to inadequate awakening response, cerebral imaging was performed, which showed multiple abscesses. The patient died shortly thereafter, and an autopsy showed fusariosis.

scholarly journals Successful Use of Posaconazole to Treat Invasive Cutaneous Fungal Infection in a Liver Transplant Patient on Sirolimus

2012 ◽  
Vol 23 (2) ◽  
pp. e44-e47 ◽  
Author(s):  
Randah Dahlan ◽  
Ameen Patel ◽  
Shariq Haider
Keyword(s):  
Liver Transplant ◽  
Transplant Patient ◽  
Organ Transplant ◽  
Candida Guilliermondii ◽  
Antifungal Drugs ◽  
High Morbidity ◽  
Solid Organ ◽  
Liver Transplant Patient ◽  
Cutaneous Infections ◽  
Metastatic Infection

Fungi are an important and common cause of cutaneous infections affecting solid organ transplant recipients. These infections can represent a primary site of infection with the potential for dissemination, or a manifestation of metastatic infection. The high morbidity and mortality associated with these infections necessitates urgent therapy with antifungal drugs; however, the interaction between these drugs and immunosuppressive therapies can be a major limitation because of drug toxicity. A case of soft tissue infection of the toe caused by Fusarium chlamydosporum and Candida guilliermondii in a liver transplant patient on sirolimus, who was successfully treated with the new antifungal agent posaconazole, is described. The pharmacokinetic interactions of sirolimus and the new triazoles, and their impact on treatment choices are briefly discussed.

scholarly journals Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 88
Author(s):  
Smaranda Gliga ◽  
Melanie Fiedler ◽  
Theresa Dornieden ◽  
Anne Achterfeld ◽  
Andreas Paul ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cmv Infection ◽  
Cellular Assays ◽  
Risk Patients ◽  
Ifn Γ ◽  
Liver Transplant Recipients

To estimate protection from cytomegalovirus (CMV) replication after solid organ transplantation, CMV serology has been considered insufficient and thus CMV immunity is increasingly assessed by cellular in vitro methods. We compared two commercially available IFN-γ ELISpot assays (T-Track CMV and T-SPOT.CMV) and an IFN-γ ELISA (QuantiFERON-CMV). Currently, there is no study comparing these three assays. The assays were performed in 56 liver transplant recipients at the end of antiviral prophylaxis and one month thereafter. In CMV high- or intermediate-risk patients the two ELISpot assays showed significant correlation (p < 0.0001, r > 0.6) but the correlation of the ELISpot assays with QuantiFERON-CMV was weaker. Results of both ELISpot assays were similarly predictive of protection from CMV-DNAemia ≥500 copies/mL [CMV pp65 T-SPOT.CMV at the end of prophylaxis: area under curve (AUC) = 0.744, cut-off 142 spot forming units (SFU), sensitivity set to 100%, specificity 46%; CMV IE-1 T-Track CMV at month 1: AUC = 0.762, cut-off 3.5 SFU, sensitivity set to 100%, specificity 59%]. The QuantiFERON-CMV assay was inferior, reaching a specificity of 23% when setting the sensitivity to 100%. In conclusion, both CMV-specific ELISpot assays appear suitable to assess protection from CMV infection/reactivation in liver transplant recipients.

Echocardiography in the Liver Transplant Patient

2021 ◽  
Vol 23 (8) ◽  
Author(s):  
Parul Kakar ◽  
James Gubitosa ◽  
Christine Gerula
Keyword(s):  
Liver Transplant ◽  
Transplant Patient ◽  
Liver Transplant Patient
Sign in / Sign up

Export Citation Format

Share Document